Computational studies on the interaction of ABO-active saccharides with the norovirus VA387 capsid protein can explain experimental binding data.
Norovirus strains are known to cause recurring epidemics of winter vomiting disease. The crystal structure of the capsid protein of VA387, a representative of the clinically important GII.4 genocluster, was recently solved in complex with histo-blood group A- and B-trisaccharides. However, the VA387 strain is known to bind also to other natural carbohydrates for which detailed structural information of the complexes is not available. In this study we have computationally explored the fit of the VA387 with a set of naturally occurring carbohydrate ligands containing a terminal alpha1,2-linked fucose. MD simulations both with explicit and implicit solvent models indicate that type 1 and 3 extensions of the ABO-determinant including ALe(b) and BLe(b) pentasaccharides can be well accommodated in the site. Scoring with Glide XP indicates that the downstream extensions of the ABO-determinants give an increase in binding strength, although the alpha1,2-linked fucose is the single strongest interacting residue. An error was discovered in the geometry of the GalNAc-Gal moiety of the published crystal structure of the A-trisaccharide/VA387 complex. The present modeling of the complexes with histo-blood group A-active structures shows some contacts which provide insight into mutational data, explaining the involvement of I389 and Q331. Our results can be applicable in structure-based design of adhesion inhibitors of noroviruses.
Koppisetty
Chaitanya A K
CA
Biognos AB, Generatorsgatan 1, 40274 Gothenburg, Sweden.
Nasir
Waqas
W
Strino
Francesco
F
Rydell
Gustaf E
GE
Larson
Göran
G
Nyholm
Per-Georg
PG
D000017:ABO Blood-Group System / Q000737:chemistry* / Q000378:metabolism*; D001665:Binding Sites; D036022:Capsid Proteins / Q000737:chemistry* / Q000378:metabolism*; D002240:Carbohydrate Sequence; D003198:Computer Simulation; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008958:Models, Molecular; D056004:Molecular Dynamics Simulation; D008969:Molecular Sequence Data; D029322:Norovirus / Q000737:chemistry* / Q000378:metabolism* / Q000472:pathogenicity; D009844:Oligosaccharides / Q000737:chemistry* / Q000378:metabolism*; D011485:Protein Binding; D012984:Software
D000017:ABO Blood-Group System; D036022:Capsid Proteins; D008024:Ligands; D009844:Oligosaccharides
J Chem Inf Model. 2009 Dec;49(12):2749-60
19994843
Nat Med. 2003 May;9(5):548-53
12692541
J Virol. 2002 Dec;76(23):12335-43
12414974
J Virol. 2004 Mar;78(6):3035-45
14990722
Carbohydr Res. 2009 Nov 2;344(16):2217-28
19758584
J Comput Chem. 2003 Sep;24(12):1504-13
12868113
J Virol. 2008 Jun;82(11):5340-7
18385236
Carbohydr Res. 2005 Apr 11;340(5):1059-64
15780270
J Virol. 2008 Nov;82(21):10756-67
18701592
J Comput Chem. 2008 Mar;29(4):622-55
17849372
J Med Virol. 2005 Sep;77(1):116-20
16032732
Proteins. 2004 May 1;55(2):383-94
15048829
J Med Virol. 2008 Jul;80(7):1296-301
18461617
J Virol. 2007 Jun;81(11):5949-57
17392366
Gastroenterol Clin North Am. 2006 Jun;35(2):275-90, viii
16880066
Glycobiology. 2009 Mar;19(3):309-20
19054801
Gastroenterology. 2002 Jun;122(7):1967-77
12055602
J Virol. 2005 Jun;79(11):6714-22
15890909
J Comput Aided Mol Des. 2009 Dec;23(12):845-52
19757090
Virology. 2008 Sep 30;379(2):324-34
18692213
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9175-80
18599458
J Biol Chem. 1995 Mar 3;270(9):4640-9
7876235
PLoS One. 2009;4(5):e5593
19440360
J Infect Dis. 2009 Sep 1;200(5):802-12
19627248
Proteins. 2006 Nov 15;65(3):712-25
16981200
Bioinformatics. 1999 Sep;15(9):767-8
10498779
J Clin Microbiol. 2007 Aug;45(8):2720-2
17537929
PLoS Med. 2008 Feb;5(2):e31
18271619
J Virol. 2005 Dec;79(24):15351-5
16306606
J Infect Dis. 2006 Nov 15;194(10):1422-7
17054072